It is likely that given the known low rate of thrombosis amongst JAK2 variant PV patients on antiplatelet or anticoagulation prophylaxis, insignificant numbers of thrombotic events would have been noted. This evidence concerns the gene JAK2 and acquired polycythemia vera.